Allogene Therapeutics, Inc. (ALLO) Stock Profile — Insider Trades & Financials

Revenue$0

Net Income-$38.8M

EPS$-0.70

Market Cap$639.9M

Price Performance

Historical data including institutional events

Loading price data...

Company Profile

David Chang

CEO & Executive Director

Company profile for Allogene Therapeutics, Inc. (ALLO) stock, with a description, list of executives, contact details and other key facts.

Founded: 2017
Employees: 1
Headquarters: SOUTH SAN FRANCISCO, CA, United States
Website: allogene.com

Peer ComparisonRevenue ($B)

▾

⚡

Core Efficiency

ROE?

-13.27%

ROA?

-9.33%

D/E Ratio?

0.42

📊

Profitability Ratios

Current Ratio?

7.93

Loading comparison...

Earnings Calendar

Filing history and next expected filing date

Next Expected Filing

Aug 15, 2026 (in 130 days)

Annual Report (10-K) — Based on filing pattern

Aug 15, 2026

Predicted10-K

Mar 12, 2026

10-KQ4 20252d after period end

Mar 12, 2026

10-KFY 202571d after period end

Nov 6, 2025

10-QQ3 20252d after period end

Aug 13, 2025

10-QQ2 20252d after period end

May 13, 2025

10-QQ1 20254d after period end

Mar 13, 2025

10-KQ4 20246d after period end

Mar 13, 2025

10-KFY 202572d after period end

Nov 7, 2024

10-QQ3 20246d after period end

Loading company sections...

Allogene Therapeutics, Inc.

Price Performance

Company Profile

Core Efficiency

Profitability Ratios

Earnings Calendar

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness